# Comphya

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/comphya

- Industry: Medical Devices & Equipment
- Headquarters: Lausanne, Switzerland
- Website: www.comphya.com/
- Total disclosed funding: $3M
- Latest round: Seed (May 3, 2019)
- Investors on record: 3

## About

Comphya SA is a medical device company specializing in the treatment of erectile dysfunction through advanced neurostimulation technology, specifically their flagship product, CaverSTIM.Founded in 2017, Comphya SA is headquartered in Lausanne, Switzerland, where it focuses on developing innovative solutions for erectile dysfunction. The company was co-founded by Nikos Stergiopoulos and Rodrigo Fraga-Silva, who leads as CEO. To date, Comphya has successfully completed five deals, with the most recent being on December 23, 2024, during which the company raised CHF 0.850 mn in a Venture Debt funding round led by Praxis Spinal Cord Institute, contributing to a total amount raised of CHF 3.000 mn.Comphya SA specializes in the development of innovative medical devices aimed at treating erectile dysfunction (ED) through its flagship product, CaverSTIM. This implantable neurostimulator is designed to restore natural penile erection by selectively activating the cavernous nerve via implanted electrodes in the pelvic cavity. CaverSTIM offers patients a self-controlled stimulation experience, facilitated through a wireless remote control, making it a user-friendly and effective alternative for individuals who do not respond to traditional oral therapies, such as those with spinal cord injuries or post-prostatectomy complications. The primary client base consists of healthcare providers and urologists who prescribe this technology to patients seeking effective ED treatments, primarily targeting markets in Europe and North America.Comphya generates revenue through direct sales of its CaverSTIM neurostimulator to healthcare institutions and medical professionals, who subsequently offer the device to patients. The transaction structure involves a B2B model, where hospitals and clinics purchase the devices for implantation procedures. Pricing details for CaverSTIM are set to align with industry standards for innovative medical technologies, ensuring accessibility for healthcare providers while reflecting the advanced nature of the product. As Comphya continues to establish its market presence, it is anticipated that the company will form partnerships with healthcare systems and urology practices to promote the adoption of its proprietary technology. In July 2025, Comphya SA raised an undisclosed amount of venture funding from unspecified investors. The round was part of a larger CHF 7.5 million series A and debt funding.

## Funding rounds

- Seed, May 3, 2019, $3M — Zürcher Kantonalbank, NEST, Verve Ventures

## Investors

- Zürcher Kantonalbank — Seed
- NEST (https://capitalatlas.ai/funds/nest) — Seed
- Verve Ventures (https://capitalatlas.ai/funds/verve-ventures) — Seed